Skip to main content
Top
Published in: Diabetes Therapy 9/2020

01-09-2020 | Fatty Liver | Original Research

Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes

Authors: Yali Zhang, Rong Shi, Liang Yu, Liping Ji, Min Li, Fan Hu

Published in: Diabetes Therapy | Issue 9/2020

Login to get access

Abstract

Introduction

Non-alcoholic fatty liver disease (NAFLD) is becoming more prevalent in patients with type 2 diabetes mellitus (T2DM) and can contribute to serious liver damage in this patient population. The aim of this study was to develop a risk nomogram for NAFLD in a Chinese population with T2DM.

Methods

A questionnaire survey, physical examination and biochemical indicator testing were performed on 874 patients with T2DM, and the collected data were used to evaluate the risk to develop NAFLD in T2DM patients. The least absolute shrinkage and selection operator (LASSO) regression analysis method was used to optimize variable selection by running cyclic coordinate descent with k-fold (tenfold in this case) cross-validation. Multivariable logistic regression analysis was applied to build a predictive model by introducing the predictors selected from the LASSO regression analysis. The nomogram was developed based on the selected variables visually. A calibration plot, receiver operating characteristic curve (ROC) and decision curve analysis (DCA) were used to validate the model, with further assessment by external validation.

Results

A total of nine predictors, namely sex, age, total cholesterol (TC), body mass index (BMI), waistline, diastolic blood pressure (DBP), serum uric acid (SUA), course of disease and high-density lipoprotein-cholesterol (HDL-C), were identified by LASSO regression analysis from a total of 24 variables studied. The model constructed using these nine predictors displayed medium prediction ability, with an area under the ROC of 0.848 in the training set and 0.809 in the validation set. The DCA curve showed that the nomogram could be applied clinically if the risk threshold was between 48 and 91%, which was found to be between 44 and 82% in the external validation.

Conclusion

Introducing sex, age, TC, BMI, waistline, DBP, SUA, course of disease and HDL-C into the risk nomogram increased its usefulness for predicting NAFLD risk in patients with T2DM.
Literature
1.
go back to reference Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98.PubMed Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98.PubMed
2.
go back to reference Kramer CK, Retnakaran R. Liver enzymes and type 2 diabetes: a complex two-way relationship. J Diabetes Complicat. 2013;27:301–2.PubMed Kramer CK, Retnakaran R. Liver enzymes and type 2 diabetes: a complex two-way relationship. J Diabetes Complicat. 2013;27:301–2.PubMed
3.
4.
go back to reference Zelnick LR, Weiss NS, Kestenbaum BR, et al. Diabetes and CKD in the United States population, 2009–2014. Clin J Am Soc Nephrol. 2017;12:1984–90.PubMedPubMedCentral Zelnick LR, Weiss NS, Kestenbaum BR, et al. Diabetes and CKD in the United States population, 2009–2014. Clin J Am Soc Nephrol. 2017;12:1984–90.PubMedPubMedCentral
5.
go back to reference Brunton S. Pathophysiology of type 2 diabetes: the evolution of our understanding. J Fam Pract. 2016;65(4 Suppl):supp_az_0416.PubMed Brunton S. Pathophysiology of type 2 diabetes: the evolution of our understanding. J Fam Pract. 2016;65(4 Suppl):supp_az_0416.PubMed
6.
go back to reference Sarparanta J, Garcia-Macia M, Singh R. Autophagy and mitochondria in obesity and type 2 diabetes. Curr Diabetes Rev. 2017;13:352–69.PubMed Sarparanta J, Garcia-Macia M, Singh R. Autophagy and mitochondria in obesity and type 2 diabetes. Curr Diabetes Rev. 2017;13:352–69.PubMed
7.
go back to reference Araujo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38(Suppl 1):47–51.PubMed Araujo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38(Suppl 1):47–51.PubMed
8.
go back to reference Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65:1096–108.PubMedPubMedCentral Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65:1096–108.PubMedPubMedCentral
9.
go back to reference Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793–801.PubMed Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793–801.PubMed
10.
go back to reference Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32–42.PubMed Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32–42.PubMed
11.
go back to reference Pang Y, Kartsonaki C, Turnbull I, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people. Hepatology. 2018;68:1308–18.PubMedPubMedCentral Pang Y, Kartsonaki C, Turnbull I, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people. Hepatology. 2018;68:1308–18.PubMedPubMedCentral
12.
go back to reference Lee YH, Cho Y, Lee BW, et al. Nonalcoholic fatty liver disease in diabetes. Part I: Epidemiology and diagnosis. Diabetes Metab J. 2019;43:31–45.PubMed Lee YH, Cho Y, Lee BW, et al. Nonalcoholic fatty liver disease in diabetes. Part I: Epidemiology and diagnosis. Diabetes Metab J. 2019;43:31–45.PubMed
13.
go back to reference Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933–66.PubMedPubMedCentral Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933–66.PubMedPubMedCentral
14.
go back to reference Li W, Xie B, Qiu S, et al. Non-lab and semi-lab algorithms for screening undiagnosed diabetes: A cross-sectional study. EBioMedicine. 2018;35:307–16.PubMedPubMedCentral Li W, Xie B, Qiu S, et al. Non-lab and semi-lab algorithms for screening undiagnosed diabetes: A cross-sectional study. EBioMedicine. 2018;35:307–16.PubMedPubMedCentral
15.
go back to reference Wang H, Zhang L, Liu Z, et al. Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram. Patient Prefer Adherence. 2018;12:1757–65.PubMedPubMedCentral Wang H, Zhang L, Liu Z, et al. Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram. Patient Prefer Adherence. 2018;12:1757–65.PubMedPubMedCentral
16.
go back to reference Latti S, Niinivehmas S, Pentikainen OT. Rocker: open source, easy-to-use tool for AUC and enrichment calculations and ROC visualization. J Cheminform. 2016;8:45.PubMedPubMedCentral Latti S, Niinivehmas S, Pentikainen OT. Rocker: open source, easy-to-use tool for AUC and enrichment calculations and ROC visualization. J Cheminform. 2016;8:45.PubMedPubMedCentral
17.
go back to reference Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.PubMedPubMedCentral Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.PubMedPubMedCentral
18.
go back to reference Zou D, Ye Y, Zou N, Yu J. Analysis of risk factors and their interactions in type 2 diabetes mellitus: a cross-sectional survey in Guilin. China J Diabetes Investig. 2017;8:188–94.PubMed Zou D, Ye Y, Zou N, Yu J. Analysis of risk factors and their interactions in type 2 diabetes mellitus: a cross-sectional survey in Guilin. China J Diabetes Investig. 2017;8:188–94.PubMed
19.
go back to reference Pawar SV, Zanwar VG, Choksey AS, et al. Most overweight and obese Indian children have nonalcoholic fatty liver disease. Ann Hepatol. 2016;15:853–61.PubMed Pawar SV, Zanwar VG, Choksey AS, et al. Most overweight and obese Indian children have nonalcoholic fatty liver disease. Ann Hepatol. 2016;15:853–61.PubMed
20.
go back to reference Bhadoria AS, Kedarisetty CK, Bihari C, et al. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: a cross-sectional study. Liver Int. 2017;37:1397–404.PubMed Bhadoria AS, Kedarisetty CK, Bihari C, et al. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: a cross-sectional study. Liver Int. 2017;37:1397–404.PubMed
21.
go back to reference Chon YE, Kim KJ, Jung KS, et al. The relationship between type 2 diabetes mellitus and non-alcoholic fatty liver disease measured by controlled attenuation parameter. Yonsei Med J. 2016;57:885–92.PubMedPubMedCentral Chon YE, Kim KJ, Jung KS, et al. The relationship between type 2 diabetes mellitus and non-alcoholic fatty liver disease measured by controlled attenuation parameter. Yonsei Med J. 2016;57:885–92.PubMedPubMedCentral
23.
go back to reference Arnetz L, Ekberg NR, Alvarsson M. Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes Metab Syndr Obes. 2014;7:409–20.PubMedPubMedCentral Arnetz L, Ekberg NR, Alvarsson M. Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes Metab Syndr Obes. 2014;7:409–20.PubMedPubMedCentral
24.
go back to reference Chen KL, Madak-Erdogan Z. Estrogens and female liver health. Steroids. 2018;133:38–433.PubMed Chen KL, Madak-Erdogan Z. Estrogens and female liver health. Steroids. 2018;133:38–433.PubMed
25.
go back to reference Wu KT, Kuo PL, Su SB, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol. 2016;10(420–5):e1. Wu KT, Kuo PL, Su SB, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol. 2016;10(420–5):e1.
26.
go back to reference Femlak M, Gluba-Brzozka A, Cialkowska-Rysz A, Rysz J. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids Health Dis. 2017;16:207.PubMedPubMedCentral Femlak M, Gluba-Brzozka A, Cialkowska-Rysz A, Rysz J. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids Health Dis. 2017;16:207.PubMedPubMedCentral
27.
go back to reference Schmidt MI, Duncan BB, Bang H, et al. Identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2005;28:2013–8.PubMed Schmidt MI, Duncan BB, Bang H, et al. Identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2005;28:2013–8.PubMed
28.
go back to reference Wilson PW, Meigs JB, Sullivan L, et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167:1068–74.PubMed Wilson PW, Meigs JB, Sullivan L, et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167:1068–74.PubMed
29.
go back to reference Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol. 2019;18:810–5.PubMed Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol. 2019;18:810–5.PubMed
30.
go back to reference Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief, no 219. Hyattsville: National Center for Health Statistics; 2015. p. 1–8. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief, no 219. Hyattsville: National Center for Health Statistics; 2015. p. 1–8.
31.
go back to reference Li S, Xiao J, Ji L, et al. BMI and waist circumference are associated with impaired glucose metabolism and type 2 diabetes in normal weight Chinese adults. J Diabetes Complicat. 2014;28:470–6.PubMedPubMedCentral Li S, Xiao J, Ji L, et al. BMI and waist circumference are associated with impaired glucose metabolism and type 2 diabetes in normal weight Chinese adults. J Diabetes Complicat. 2014;28:470–6.PubMedPubMedCentral
32.
go back to reference Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
33.
go back to reference Malone JIHansen BC. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite? Pediatr Diabetes. 2019;20:5–9. Malone JIHansen BC. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite? Pediatr Diabetes. 2019;20:5–9.
34.
go back to reference Cryer MJ, Horani T, DiPette DJ. Diabetes and hypertension: a comparative review of current guidelines. J Clin Hypertens (Greenwich). 2016;18:95–100. Cryer MJ, Horani T, DiPette DJ. Diabetes and hypertension: a comparative review of current guidelines. J Clin Hypertens (Greenwich). 2016;18:95–100.
35.
go back to reference [No Authors Listed]. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11:309–17. [No Authors Listed]. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11:309–17.
36.
go back to reference Pechere-Bertschi A, Greminger P, Hess L, Philippe J, Ferrari P. Swiss Hypertension and Risk Factor Program (SHARP): cardiovascular risk factors management in patients with type 2 diabetes in Switzerland. Blood Press. 2005;14:337–44.PubMed Pechere-Bertschi A, Greminger P, Hess L, Philippe J, Ferrari P. Swiss Hypertension and Risk Factor Program (SHARP): cardiovascular risk factors management in patients with type 2 diabetes in Switzerland. Blood Press. 2005;14:337–44.PubMed
37.
go back to reference Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603–15.PubMed Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603–15.PubMed
38.
go back to reference Lombardi R, Pisano G, Fargion S. Role of serum uric acid and ferritin in the development and progression of NAFLD. Int J Mol Sci. 2016;17:548.PubMedPubMedCentral Lombardi R, Pisano G, Fargion S. Role of serum uric acid and ferritin in the development and progression of NAFLD. Int J Mol Sci. 2016;17:548.PubMedPubMedCentral
39.
go back to reference Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483–95.PubMed Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483–95.PubMed
40.
go back to reference Shih MH, Lazo M, Liu SH, et al. Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc. 2015;114:314–20.PubMed Shih MH, Lazo M, Liu SH, et al. Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc. 2015;114:314–20.PubMed
41.
go back to reference Fan N, Zhang L, Xia Z, et al. Sex-specific association between serum uric acid and nonalcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Res. 2016;2016:3805372.PubMedPubMedCentral Fan N, Zhang L, Xia Z, et al. Sex-specific association between serum uric acid and nonalcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Res. 2016;2016:3805372.PubMedPubMedCentral
42.
go back to reference Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev. 2009;30:96–116.PubMedPubMedCentral Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev. 2009;30:96–116.PubMedPubMedCentral
43.
go back to reference Han K, Yun JS, Park YM, et al. Development and validation of a risk prediction model for severe hypoglycemia in adult patients with type 2 diabetes: a nationwide population-based cohort study. Clin Epidemiol. 2018;10:1545–59.PubMedPubMedCentral Han K, Yun JS, Park YM, et al. Development and validation of a risk prediction model for severe hypoglycemia in adult patients with type 2 diabetes: a nationwide population-based cohort study. Clin Epidemiol. 2018;10:1545–59.PubMedPubMedCentral
44.
go back to reference Abraldes JG, Bureau C, Stefanescu H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study. Hepatology. 2016;64:2173–84. Abraldes JG, Bureau C, Stefanescu H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study. Hepatology. 2016;64:2173–84.
45.
go back to reference Cappellari M, Turcato G, Forlivesi S, et al. STARTING-SICH nomogram to predict symptomatic intracerebral hemorrhage after intravenous thrombolysis for stroke. Stroke. 2018;49:397–404.PubMed Cappellari M, Turcato G, Forlivesi S, et al. STARTING-SICH nomogram to predict symptomatic intracerebral hemorrhage after intravenous thrombolysis for stroke. Stroke. 2018;49:397–404.PubMed
46.
go back to reference Chung SM, Park JC, Moon JS, Lee JY. Novel nomogram for screening the risk of developing diabetes in a Korean population. Diabetes Res Clin Pract. 2018;142:286–93.PubMed Chung SM, Park JC, Moon JS, Lee JY. Novel nomogram for screening the risk of developing diabetes in a Korean population. Diabetes Res Clin Pract. 2018;142:286–93.PubMed
47.
go back to reference Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88:1254–64.PubMedPubMedCentral Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88:1254–64.PubMedPubMedCentral
48.
go back to reference Radaelli MG, Martucci F, Perra S, et al. NAFLD/NASH in patients with type 2 diabetes and related treatment options. J Endocrinol Invest. 2018;41:509–21.PubMed Radaelli MG, Martucci F, Perra S, et al. NAFLD/NASH in patients with type 2 diabetes and related treatment options. J Endocrinol Invest. 2018;41:509–21.PubMed
49.
go back to reference Ahmed MH, Husain NEO, Almobarak AO. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? J Family Med Primary Care. 2015;4:45–52. Ahmed MH, Husain NEO, Almobarak AO. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? J Family Med Primary Care. 2015;4:45–52.
Metadata
Title
Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes
Authors
Yali Zhang
Rong Shi
Liang Yu
Liping Ji
Min Li
Fan Hu
Publication date
01-09-2020
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 9/2020
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-020-00893-z

Other articles of this Issue 9/2020

Diabetes Therapy 9/2020 Go to the issue